KDR and neoplasm: Taking advantage of vascular endothelial growth factor receptor 2 (VEGFR-2) overexpression in cancer cells and tumor neovasculature, Liu et al. [43] pioneered the “one-double targeting” strategy, meaning one ligand for double (tumor and vascular) targeting, with Flk-1(A-3) mAb.